^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Cyramza (ramucirumab) (VEGFR-2 inhibitor) + Tukysa (tucatinib) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Published date:
10/16/2023
Excerpt:
MOUNTAINEER-02 is a global trial evaluating TUC 300 mg BID + T (6 then 4 mg/kg D1,15) + P (D1, 8, 15) + R (8 mg/kg D1, 15) every 28 days in pts with previously treated, locally advanced unresectable or metastatic HER2+ GEC….the combination of TUC+T+P+R was tolerable with encouraging antitumor activity in pts with previously treated HER2+ GEC.
Secondary therapy:
paclitaxel
Trial ID:
